Landing Pad Screening for Site-Specific Provirus Integration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current retroviral vectors, particularly lentiviral vectors, face challenges with genotoxicity and safety concerns, and their production is costly and hampers scalability and reproducibility in gene therapy applications.

Innovation Solution

Development of landing pad cassettes for site-specific integration of provirus constructs, accompanied by an assay for rapid evaluation of vector-associated genotoxicity and efficacy, using polynucleotides with specific recombination sites and markers for enhanced safety and efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If retroviral vectors are used for gene therapy, then long-term transgene expression and therapeutic efficacy are achieved, but genotoxicity and safety concerns arise due to random integration into host genome

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidgenotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent prepares landing pad cassettes in advance that are integrated into safe genomic loci before viral transduction. These pre-prepared integration sites contain necessary regulatory elements and markers, allowing the viral vector to simply insert into the predetermined safe location rather than randomly integrating throughout the genome, thereby preventing genotoxicity while ensuring therapeutic efficacy

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The landing pad cassette acts as an intermediary element between the viral vector and the host genome. It provides a controlled integration interface with specific recombination sites that mediate the insertion process, ensuring that the viral genetic material integrates only at predetermined safe locations rather than randomly throughout the genome, thus resolving the contradiction between integration efficiency and genotoxicity

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If traditional lentiviral vector production methods are used, then viral vectors can be produced, but the process is costly and hampers scalability and reproducibility

Engineering Contradiction:

Improvevector production capacityVSAvoidmanufacturing cost and scalability

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent segments the gene therapy system into distinct functional modules: landing pad cassettes containing integration sites and markers, and viral vectors containing therapeutic genes. This segmentation allows independent optimization and standardized production of each component, enabling scalable manufacturing through modular assembly rather than complex integrated processes, thereby improving ease of manufacture while maintaining productivity

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the fundamental parameter of integration methodology from random to site-specific. By using defined recombination sites in landing pad cassettes, the system achieves controlled integration that can be standardized and scaled. This parameter change enables reproducible manufacturing processes with consistent outcomes, directly addressing the scalability and reproducibility issues while maintaining high vector production capacity

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250340866A1A screening method

Publication Date: 2025.11.06 CENTEON LLC

AI summary

The present disclosure relates to landing pads, proviruses and methods of use thereof.